Hepion Pharmaceuticals, Inc 8-K, filed Jun 12, 2025
Hepion Pharmaceuticals, Inc. (HEPA)
About this 8-K
Hepion Pharmaceuticals, Inc filed this 8-K on June 12, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | IRS Employer | ||
| of incorporation or organization) | File Number) | Identification No.) |
(Address of principal executive offices)
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
| OTC Markets |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 12, 2025, Hepion Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Meeting”).
As of April 24, 2025, the record date for the Meeting, there were 10,927,279 shares of our common stock outstanding (including 3 shares of common stock issuable upon conversion of the Series A Preferred Stock).
At the Meeting, the stockholders voted on the following four proposals and cast their votes as follows:
1. To elect the four (4) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of John P. Brancaccio, Timothy Block, Kaouthar Lbiati and Michael Purcell.
| Name | Votes For | Withhold | Broker Non-Vote | |||
| John P. Brancaccio | 188,144 | 315,628 | 5,460,693 | |||
| Timothy Block | 298,210 | 205,562 | 5,460,693 | |||
| Kaouthar Lbiati | 284,854 | 218,919 | 5,460,692 | |||
| Michael Purcell | 282,950 | 220,823 | 5,460,692 |
2. To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2025.
| Votes For | Votes Against | Votes Abstained | Broker Non-Vote | |||
| 4,755,685 | 1,166,314 | 42,466 | - |
3. To approve an amendment to the Company’s Certificate of Incorporation, as amended to effect a reverse stock split of the Company’s common stock at a ratio of between 1-for-5 and 1-for-20 (the “Reverse Stock Split”), with such ratio to be determined at the sole discretion of the board of directors of the Company (the “Board”) and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion.
| Votes For | Votes Against | Votes Abstained | Broker Non-Vote | |||
| 2,251,227 | 3,696,326 | 16,907 | 5 |
4. To approve, on an advisory basis, the compensation of the Company’s named executive officers, referred to as “say-on-pay.
| Votes For | Votes Against | Votes Abstained | Broker Non-Vote | |||
| 162,156 | 337,190 | 4,426 | 5,460,693 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 12, 2025
| HEPION PHARMACEUTICALS, INC. | ||
| By: | /s/ John Brancaccio | |
| John Brancaccio | ||
| Interim Chief Executive Officer | ||